Prognostic value of ALC following BCMA CAR T-cell therapy in multiple myeloma

Incorporating BCMA-targeted CAR-T therapy in the frontline treatment of multiple myelomaПодробнее

Predictors of T Cell Expansion and Clinical Responses Following CART-BCMA for RRMMПодробнее

CAR T-cells in Multiple MyelomaПодробнее

Anti-BCMA CAR T-cell therapy for multiple myeloma: latest studiesПодробнее

CAR T-Cells Multiple Myeloma: Adam Sperling, MD, PhDПодробнее

The value of CAR-T cell therapy for the treatment of R/R multiple myelomaПодробнее

Abnormal serum immunofixation patterns following BCMA CAR-T in multiple myelomaПодробнее

Prognostic value of early bone marrow and PET MRD assessment in CAR-T therapy for multiple myelomaПодробнее

Biallelic BCMA loss causes anti-BCMA CAR-T resistance in myelomaПодробнее

Phase 1 Study PHE885 BCMA-Directed CAR-T Cell Therapy for RRMM | Adam Sperling, MD, PhD | ASCO 2023Подробнее

Anti-BCMA CAR T-cells in myeloma: what data do we have so far?Подробнее

Natalie Callander, MD, Discusses BCMA CAR T Cell Therapy for Multiple MyelomaПодробнее

Dr. Shah on BCMA-Directed CAR T-Cell Therapy Research in R/R Multiple MyelomaПодробнее

Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple MyelomaПодробнее

What factors contribute to resistance to BCMA-targeted CAR T-cell therapies in multiple myeloma?Подробнее

What is CAR-T Cell Therapy?Подробнее

BCMA-Targeted CAR T-Cell Therapy for MyelomaПодробнее

Anti-BCMA CAR T cell therapy for multiple myelomaПодробнее

Can a patient use a different CAR-T target after receiving BCMA directed therapy?Подробнее